← Back to all trials
Completed
NCT07786168
Roxadustat Versus Erythropoietin for Anaemia Treatment in Diabetic Nephropathy
Conditions: Diabetic Nephropathy, Anemia, Chronic Kidney Disease
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: NA
Enrollment: 64
Sponsor: Hanzla Arshad
Location: Sheikh Zayed Hospital Lahore
Summary
This randomized controlled trial compared roxadustat with erythropoietin for the treatment of anaemia in patients with diabetic nephropathy and chronic kidney disease. A total of 64 patients aged 18 to 75 years were enrolled at the Department of Nephrology, Sheikh Zayed Hospital, Lahore, and randomly assigned in a 1:1 ratio to two treatment groups. Participants in the roxadustat group received roxadustat 100 mg orally three times per week, while participants in the erythropoietin group received recombinant erythropoietin 4000 IU subcutaneously twice weekly. Participants were followed for three months. The primary objective was to compare the change in haemoglobin level between the two treatment groups after treatment.
Eligibility Criteria
Inclusion Criteria:
Age 18 to 75 years. Confirmed type 1 or type 2 diabetes mellitus. Chronic kidney disease stage 3a, 3b, 4, or 5, based on estimated glomerular filtration rate calculated using the 2021 CKD-EPI creatinine equation.
Anaemia, defined as haemoglobin \
Source: ClinicalTrials.gov (NCT07786168). StuddyBuddy aggregates publicly available trial information.
